Related references
Note: Only part of the references are listed.Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
Lykke Midtboll Ornbjerg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study
Shuji Asai et al.
MODERN RHEUMATOLOGY (2018)
Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-
Kosuke Ebina et al.
PLOS ONE (2018)
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
Florenzo Iannone et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis
Ennio Giulio Favalli et al.
ARTHRITIS CARE & RESEARCH (2017)
Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry
Dong-Jin Park et al.
CLINICAL RHEUMATOLOGY (2017)
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability
Florenzo Iannone et al.
CLINICAL RHEUMATOLOGY (2016)
Tumour necrosis factor-a inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation
Mark Corbett et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Ankylosing Spondylitis and Axial Spondyloarthritis
Joel D. Taurog et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry
Ennio Giulio Favalli et al.
ARTHRITIS CARE & RESEARCH (2016)
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Atul Deodhar et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
J. Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides
Martina Biggioggero et al.
DRUG DEVELOPMENT RESEARCH (2014)
Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry
Chi Chiu Mok et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2014)
Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Marta Fabbroni et al.
MEDIATORS OF INFLAMMATION (2014)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Indirect comparison of the effects of anti-TNF biological agents in patients with Ankylosing Spondylitis by means of a Mixed Treatment Comparison performed on efficacy data from published randomised, controlled trials
A. Migliore et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China
Manlong Xu et al.
RHEUMATOLOGY (2011)
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study
Suzanne Arends et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Share Paper
